Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Researchers want to find the best dose of the antibody-drug conjugate LY4101174 to treat advanced bladder and prostate cancers. The people in this study have bladder or prostate cancer that came back or keeps growing after treatment. 
Researchers want to learn how well zelenectide pevedotin works against advanced breast cancer. The people in this study have breast cancer that has come back, spread, or cannot be surgically removed. Their cancers are hormone receptor positive/HER2-negative or are triple negative. In addition, their tumor cells have an amplification (too many copies) of a gene called Nectin4.
Researchers want to find the best dose of CRD3874-SI to use in people with sarcoma or Merkel cell carcinoma (MCC). The people in this study have sarcoma or MCC that has spread. CRD3874-SI attaches to a type of protein called a STING. This protein encourages immune cells to kill cancer cells, which may slow or stop cancer growth. CRD3874-SI is given intravenously (by vein).
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Researchers want to find the best dose of iberdomide that can be given with elranatamab in people with multiple myeloma. The people in this study have multiple myeloma that came back or keeps growing even after treatment.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Women with a mutation in the BRCA1 or BRCA2 genes are at increased risk for hereditary breast and ovarian cancer. However, the cancer risk estimates for these gene mutations are currently wide-ranging and non-specific. A new form of genetic testing, called "genetic risk modifier testing," may give women with BRCA1/2 gene mutations more specific estimates of their risk of developing breast cancer.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Researchers want to find the best doses of BNT324 and BNT327 when given together to treat lung cancer. The people in this study have lung cancer that spread and came back or got worse after treatment.
The usual treatment for brain metastases (cancer that spread to the brain) is a single treatment of stereotactic radiosurgery (SRS). SRS uses special equipment to position the patient and precisely give a single large dose of radiation to a tumor.
